Butein Alleviates Non-Alcoholic Steatohepatitis in Leptin-Deficient Mice by Modulating the PDE4/cAMP/p-CREB Pathway

Area of Science:

• Hepatology
• Pharmacology
• Molecular Biology

Background:

• Non-alcoholic steatohepatitis (NASH) is a growing liver disease with limited treatment options.
• Flavonoids, like butein, possess anti-inflammatory and antioxidant properties.
• Butein's therapeutic potential in NASH remains largely unexplored.

Purpose of the Study:

• To investigate the therapeutic effects of butein in experimental NASH models.
• To elucidate the molecular mechanisms underlying butein's action in NASH.
• To evaluate butein's impact on glucolipid metabolism, inflammation, and fibrosis.

Main Methods:

• Utilized a leptin-deficient (ob/ob) mouse model of NASH induced by a GAN diet.
• Employed in vitro models using HepG2 and LX-2 cells treated with palmitic acid.
• Assessed oxidative stress, inflammation, fibrotic markers, and the PDE4/cAMP/p-CREB pathway.

Main Results:

• Butein significantly improved glucolipid metabolism, reduced hepatic inflammation, and ameliorated liver fibrosis in mice.
• In vitro, butein attenuated palmitic acid-induced oxidative stress in HepG2 cells.
• Butein decreased inflammatory and fibrotic responses in LX-2 cells.

Conclusions:

• Butein demonstrates protective effects against NASH progression.
• The PDE4/cAMP/p-CREB signaling pathway is implicated in butein's therapeutic action.
• Butein is a potential therapeutic candidate for NASH, requiring further clinical studies.